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Background. A study was conducted among newly registered HIV-positive tuberculosis (TB) patients systematically offered
anti-retroviral treatment (ART) in a district hospital in rural Malawi in order to a) determine the acceptance of ART b) conduct
a geographic mapping of those placed on ART and c) examine the association between ‘‘cost of transport’’ and ART
acceptance. Methodology/Principal Findings. A retrospective cross-sectional analysis was performed on routine program
data for the period of February 2003 to July 2004. Standardized registers and patient cards were used to gather data. The place
of residence was used to determine road distances to the Thyolo district hospital. Cost of transport from different parts of the
district was based on the known cost for public transport to the road-stop closest to the patient’s residence. Of 1,290 newly
registered TB patients, 1,003(78%) underwent HIV-testing of whom 770 (77%) were HIV-positive. 742 of these individuals
(pulmonary TB=607; extra-pulmonary TB=135) were considered eligible for ART of whom only 101(13.6%) accepted ART. Cost
of transport to the hospital ART site was significantly associated with ART acceptance and there was a linear trend in
association between cost and ART acceptance (X
2 for trend=25.4, P,0.001). Individuals who had to pay 50 Malawi Kwacha (1
United States Dollar=100 Malawi Kwacha, MW) or less for a one-way trip to the Thyolo hospital were four times more likely to
accept ART than those who had to pay over 100 MW (Adjusted Odds ratio=4.0, 95% confidence interval: 2.0–8.1, P,0.001).
Conclusions/Significance. ART acceptance among TB patients in a rural district in Malawi is low and associated with cost of
transport to the centralized hospital based ART site. Decentralizing the ART offer from the hospital to health centers that are
closer to home communities would be an essential step towards reducing the overall cost and burden of travel.
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INTRODUCTION
Tuberculosis (TB) is one of the most common causes of morbidity
and mortality in HIV positive populations [1,2] and TB often brings
the HIV-positive individual to medical attention. Since TB patients
constitute a readily identifiable group in the health system for HIV-
testing, they thus offer an opportunity for introducing HIV-related
interventions including antiretroviral treatment (ART) [3].
Malawi, a small resource-poor country in southern Africa, has
an estimated national HIV prevalence rate of 9%,[4] and 77% of
new patients registered with TB are co-infected with HIV [5].
The Malawi ART guidelines [6] recommend that HIV-positive
individuals assessed to be in World Health Organization (WHO)
clinical stages III and IV are eligible for ART. As HIV-positive
individuals with pulmonary TB (PTB) are classified as WHO stage
III and those with extrapulmonary TB (EPTB) as WHO stage IV,
all such TB patients are considered eligible for ART in Malawi.
In Thyolo district, rural southern Malawi, ART was initiated in
the main public hospital of the district in early 2003. However,
despite a systematic offer of ART to all HIV-positive TB patients,
acceptance of ART in this group was found to be at a low 13% [7].
It is likely that multiple factors might be influencing ART
acceptance in HIV-positive TB patients in this setting, but these
are at present not well characterized. We hypothesized that the
‘‘cost of transport’’ to a single, centralized ART delivery site in
a poor rural setting where public transport networks are poorly
developed is likely to be one of such factors, and a possible barrier
for ART acceptance.
We conducted a study in Thyolo in order to a) determine the
acceptance of ART among newly registered HIV-positive TB
patients; b) conduct a geographic mapping of those placed on
ART; and c) examine the association between ‘‘cost of transport’’
and ART acceptance.
METHODS
Study setting and management of TB
This study was conducted between February 2003 and July 2004
in Thyolo district, a rural region in Southern Malawi with
approximately 500 000 inhabitants. All newly registered HIV-
positive TB patients presenting to the main public hospital in the
district (Thyolo hospital) were involved in the study. TB patients
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whole blood testing kits, according to the WHO strategy II for
HIV antibody testing [8]. Cotrimoxazole prophylaxis is offered to
all HIV-positive TB patients at a dose of 960 mg daily provided
there are no contraindications.
Anti-TB treatment is based on national guidelines and has been
described before [6]. In the initial phase of treatment, patients are
admitted to the hospital TB wards for 2 weeks during which they
receive directly observed anti-TB treatment. Patients are then
allowed to go home, and receive their remaining 6 weeks of initial
phase anti-TB treatment under supervision at a health center, or
from a guardian. A guardian in this context refers to a family
member or someone in the neighbourhood who will ensure that
the patient does take the prescribed treatment. They are then
placed on the six-month continuation phase of treatment where
they receive isoniazid and ethambutol on a monthly basis from
health centers (decentralized sites). Cotrimoxazole is also provided
and made available at all health centers for continued prophylaxis.
ART for HIV-positive TB patients
The first line ART regimen in Malawi is a fixed dose combination
of Stavudine (d4T), Lamivudine (3TC) and Nevirapine (NVP) [6].
Because of concern about drug interactions between rifampicin
and nevirapine, ART is offered to all HIV-positive TB patients
only after completing the initial two months of anti-TB treatment.
HIV-positive TB patients are systematically informed of the
offer of ART and requested to return to the hospital HIV-ART
clinic eight weeks after starting anti-TB treatment in conjunction
with a patient guardian to prepare for ART initiation. Once
started on ART, patients are reviewed back at the HIV-ART
clinic after two weeks. From then on, provided there are no side
effects, patients are seen monthly at the ART clinic and given
drugs every 28 days indefinitely. ART and anti-TB treatment are
offered free of charge in Thyolo and at the time of the study the
Thyolo hospital was the only ART delivery site in the district.
Data collection and statistical analysis
The counseling, TB and ART registers [9] as well as patient cards
were used to gather basic socio-demographic data, as well as
information on HIV testing, type of TB and ART uptake.
The place of residence as indicated on the TB patient card and
register was used to determine road distances to the Thyolo district
hospital. Cost of transport from different parts of the district were
based on the known cost for public transport to the road-stop
closest to the patients residence. Two traditional authorities
namely Khwethmule and Thukuta traditional did not have TB
treatment units. Data on ART acceptance for these two areas was
thus included with that of Nsabwe, Changata, and Mpuka
depending on where the patient was being followed for TB
treatment.
Newly registered HIV-positive TB patients placed on ART
were designated as the dependent variable for identifying potential
associations. The measures of risk were determined by crude odds
ratios (OR) and adjusted odds ratios (adjusted OR). Odds ratios
were adjusted using multi-variate logistic regression, and all related
P-values are based on the wald test. The x
2 test for trend was used
to test for linear trends. The level of significance was set at P=0.05
or less and 95% confidence intervals were used throughout.
RESULTS
Characteristics of the study population
There were 1290 patients registered for TB during the study
period (FIGURE 1). HIV testing was done in 1003 (78%) of
whom 770(77%) were found to be HIV positive. During the
intensive phase of anti-TB treatment, 19 HIV positive TB patients
died and 9 were transferred out of the district; these individuals are
excluded from the study. Of the 742 HIV-positive TB patients
who completed the intensive phase of anti-TB treatment and were
considered eligible for ART, there were 420 women and 322 men
(median age: 32 years, range 2-70 years). 376 (51%) patients were
married while 366 were single (unmarried, divorced or widowed ).
The great majority (76%) of TB patients were subsistence farmers
while tea and coffee estate employees, petty traders and students
comprised the rest. There were 607 (82%) individuals with
pulmonary TB (smear-positive or negative) and 135 individuals
with EPTB. 716 (93%) of the 770 HIV-positive TB patients were
placed on cotrimoxazole prophylaxis.
Uptake of ART among HIV-positive TB patients
Of 742 HIV-positive TB patients who completed the intensive
phase of anti-TB treatment and were offered ART, only
101(13.6%) were started on ART (FIGURE 1).
Geographic mapping of HIV positive TB patients
placed on ART in Thyolo district
FIGURE 2 shows the single ART delivery site (Thyolo hospital),
the geographic distribution of HIV-positive TB patients within
traditional authorities (or from borderline areas), and the re-
spective proportions who were placed on ART. The median
distance that HIV-positive TB patients had to travel to get to the
Thyolo hospital was 22 km (range 5 to 65 km) and the median
cost for transport was 70 Malawi kwacha (range 30 to 270 kwacha,
1 United States Dollar, USD=100 Malawi Kwacha). 79 (78%) of
101 TB patients placed on ART came from three traditional
authorities that lie within the proximity of the ART delivery site
and where cost of transport was less than 70 Malawi kwacha.
Factors associated with ART uptake
TABLE 1 shows the association between various factors and ART
acceptance among HIV-positive TB patients. Cost of transport to
the hospital ART site was significantly associated with ART
acceptance and there was a linear trend in association between
cost and ART acceptance (X
2 for trend=25.4 P=,0.001).
Individuals who had to pay 50 Malawi Kwacha (half a United
States dollar) or less for a one way trip to the Thyolo hospital were
four times more likely to take up the offer of ART than those who
had to pay 100 (or more) Malawi Kwacha ($1 USD).
DISCUSSION
This study shows that ART acceptance among TB patients in
a rural district in Malawi is low and associated with cost of
transport to the centralized hospital based ART site. The higher
the cost of transport to the hospital based ART delivery site, the
less probable it is that a TB patient accepts ART.
Distance to the hospital facility per-se was not significantly
associated with ART uptake and this is likely linked to the fact that
cost of transport is much more related to the presence (or not) of
public transport networks. The relationship between distance and
cost of transport is not proportional, because where public
transport is well developed, the cost for a given distance would
be relatively less and vise-versa.
The great majority of TB patients in our setting are poor
subsistence farmers earning less than 4 USD per week [10].
Evidence from other similar settings in Malawi has revealed that
access costs linked to establishing a TB diagnosis and starting
Transport Costs and ART
PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e121treatment alone amounts to seven months or more of annual
income for such individuals [11]. Thus, the payment of even just
one 1 USD for a return trip to an ART site will account for at least
25% of weekly net-revenue, and the financial predicament of TB
patients at the time of starting ART might mean that they are
simply too impoverished to afford such a sum linked to accessing
ART. There is also recent evidence from the ART-Link collabor-
ation that shows that mortality of HIV-1 infected patients in the
first year of antiretroviral therapy was increased in ART-programs
that charged user fees [12].
In contrast to the current centralized offer of ART, cotrimox-
azole prophylaxis has been decentralized along with anti-TB
treatment and the drug is made available in all health centers.
Patients thus receive their monthly supply of cotrimoxazole along
with anti-TB drugs at sites close to their home communities. The
overall burden and particularly cost of transport is thus minimized.
In contrast to ART, the uptake of cotrimoxazole in this cohort of
patients is 93%, and other studies in the same setting have
demonstrated that adherence to cotrimoxazole both during and
after anti-TB treatment is close to 94% [10,13].
One of the logical ways forward in trying to minimize the out of
pocket transport expenses associated with accessing ART from
a centralized site would be to decentralize ART to health centers
in a similar manner as has been done for anti-TB treatment
and cotrimoxazole. This would have a number of important
advantages:
First, from the patient perspective, the overall travel related
burden would be reduced. This would be of particular relevance to
ill TB patients who live in relatively remote areas and are thus
unable to make multiple journeys either due to cost or other
burdens of travel [l0,14].
Second, decentralization of ART-initiation to health centers
would mean integration of both TB and HIV/AIDS services
within one health facility and involvement of the same team with
Figure 1. Uptake of antiretroviral treatment among tuberculosis patients. *Individuals who had completed their initial phase (2 months) of anti-TB
treatment and were supposed to start ART during the period April 2003 to September 2004.
doi:10.1371/journal.pone.0000121.g001
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influence the patient’s perception of the link between the two
diseases, which in turn may positively influence ART-seeking
behavior among TB patients.
Third, the great majority of TB patients tend to feel better after
completing the two first months of the intensive phase of anti-TB
treatment. These patients would probably prefer to continue
treatment in health centers close to their communities [15,16].
This patient friendly approach based around health centers, if
coupled with supportive community involvement, is also likely to
be more cost-effective in the long run [17,18].
Finally, from a district hospital perspective, the workload on
a centralized hospital-based ART clinic will be progressively
reduced as ART initiation becomes progressively decentralized to
health centres. Despite these obvious advantages, decentralizing
the initiation of ART to health centers raises a number of opera-
tional implications that will need to be addressed. First, selected
health centers would need to have appropriate infrastructure to be
Figure 2. Geographic distribution of tuberculosis cases placed on ART. $ART delivery site, Thyolo hospital. Numbers and percentages (%)
represent the proportion of HIV-positive TB patients placed on ART.
doi:10.1371/journal.pone.0000121.g002
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ment of opportunistic infections, support and education of patients
for ART, registration and initiation of ARV therapy and follow-up
of patients. Second, there has to be adequate human resources to
perform these additional tasks. Currently only 50% of available
posts in the Ministry of Health in Malawi are filled [17] and it is
estimated that the minimum additional staff requirement to
initiate first-line ART would include a full-time clinical officer (or
nurse), a counselor and a clerk [6]. Health centers might need time
to build up these additional human resources. An interim solution ,
might be to introduce a mobile district based ‘‘ART initiation
team’’. Third, health staff will need to be trained and certified as
being competent to manage ART. Finally, registration and
monitoring tools will also have to be placed at health centers
and a mechanism put in place to ensure regular ART drug supply,
drug security and supervision.
The strengths of this study are that an impressive proportion of
TB patients underwent HIV-testing and were included in the
analysis, and as the data comes from a routine TB program setting
the results reflect the reality on the ground. However, this study
was only designed to examine the association between cost of
transport and ART acceptance and there are a number if other
relevant questions that cannot be answered here and which merit
further specific research: a) is the rather long (8 week) waiting time
between the initiation of anti-TB treatment and ART influencing
ART acceptance ? b) are TB patients who feel better with anti-TB
treatment and cotrimoxazole not appreciating the extra need for
ART? c) are patients in the district hospital not being educated
enough about HIV/AIDS to realize the importance of ART? and
d) are there other unrecognized barriers to ART uptake ?
Whatever might be the eventual answers to these and other
questions, in the meantime, decentralizing the ART offer from the
hospital to health centers that are closer to home communities
would be an essential step towards reducing the overall cost and
burden of travel. Despite the operational challenges, and hard
work ahead, this would seem a worthwhile goal to strive for!
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Table 1. Factors associated with uptake of anti-retroviral treatment among tuberculosis (TB) patients.
..................................................................................................................................................
Variables Placed on ART
a(%) OR
b Adjusted OR
c P
d
Gender
Women 64/420 (15.2) 1 1
Men 37/322 (11.5) 1.4 (0.9–2.1) 1.4 (0.8–2.3) 0.2
Age
.35 years 23/240 (9.6) 1 1
#35 years 78/102 (15.5) 1.7 (1.1–2.8) 1.6 (0.9–2.6) 0.09
Marital status
Married 46/376 (12.3) 1 1
Single/divorced/widowed 55/366 (15) 1.3 (0.8–1.9) 1.2 (0.7–1.8) 0.5
TB
e Type
Pulmonary
f 79/607 (13) 1 1
Extrapulmonary 22/135 (18.2) 1.3 (0.7–2.1) 1.3 (0.8–2.2) 0.3
Occupation
Farmers 73/563 (13) 1 1
Others
g 28/179 (15.6) 1.2 (0.8–2.0) 1.5 (0.9–2.5) 0.1
Distance from ART site
.20 km 39/386 (10.1) 1 1
#20 km 62/356 (17.4) 1.9 (1.2–2.9) 1.1 (0.6–1.8) 0.8
Cost of transport to ART site
h
.100 Kwacha
i 14/251 (5.6) 1 1
51–100 Kwacha 32/227 (14.1) 2.8 (1.4–5.4) 2.6 (1.2–5.9) 0.02
#50 Kwacha 55/264 (20.8) 4.5 (2.4–8.2) 4.0 (2.0–8.1) ,0.001
X
2 for trend=25.4 , P=,0.001
aAntiretroviral treatment
bOdds ratio; 95% confidence intervals in parentheses
cAdjusted for gender, age, marital status, type of tuberculosis, occupation, distance from ART delivery site; and cost of transport to the ART delivery site.
dP-value for adjusted odds ratio
eTuberculosis
fPulmonary TB: Smear positive and smear negative
gEstate employees, petty traders and students
hNo interaction between cost of transport to ART site and distance from ART site.
iLocal currency in Malawi (100 Malawi Kwacha=1 United States Dollar);
doi:10.1371/journal.pone.0000121.t001
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